Evaluating sustained adherence to ibrutinib in previously treated CLL - European Medical Journal

Evaluating sustained adherence to ibrutinib in previously treated CLL

Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, of North Shore-LIJ Cancer Institute, Lake Success, NY, discusses the results of an analysis that evaluated the effect of a once-daily 420 mg dose of ibrutinib, a Bruton’s tyrosine kinase inhibitor, on progression-free survival in patients with previously treated chronic lymphocytic leukaemia (CLL) from the phase 3 RESONATE trial.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now